KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $62.4 million.

  • Jazz Pharmaceuticals' Change in Account Payables rose 58755.28% to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.7 million, marking a year-over-year increase of 36233.23%. This contributed to the annual value of -$20.1 million for FY2024, which is 30902.84% down from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Change in Account Payables stood at $62.4 million, which was up 58755.28% from -$12.7 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Change in Account Payables' 5-year high stood at $62.4 million during Q3 2025, with a 5-year trough of -$32.0 million in Q2 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Change in Account Payables had a median value of -$142000.0 in 2021 and averaged $5.5 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Change in Account Payables skyrocketed by 2049366.2% in 2022 and then crashed by 104251.58% in 2023.
  • Jazz Pharmaceuticals' Change in Account Payables (Quarter) stood at $37.9 million in 2021, then crashed by 140.72% to -$15.4 million in 2022, then surged by 47.43% to -$8.1 million in 2023, then soared by 61.31% to -$3.1 million in 2024, then surged by 2089.09% to $62.4 million in 2025.
  • Its Change in Account Payables stands at $62.4 million for Q3 2025, versus -$12.7 million for Q2 2025 and $19.1 million for Q1 2025.